https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27851 Wed 11 Apr 2018 16:06:40 AEST ]]> Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20844 TP53INP1 was found to be one of the genes most significantly repressed by HDAC2 and N-Myc according to Affymetrix microarray gene expression datasets. HDAC2 and N-Myc reduced TP53INP1 gene expression by direct binding to the TP53INP1 gene promoter, leading to transcriptional repression of TP53INP1, p53 protein de-phosphorylation at serine 46, neuroblastoma cell proliferation and survival. Moreover, low levels of TP53INP1 expression in human neuroblastoma tissues correlated with high levels of N-Myc expression and poor patient outcome, and the BET bromodomain inhibitors JQ1 and I-BET151 reduced N-Myc expression and reactivated TP53INP1 expression in neuroblastoma cells. These findings identify TP53INP1 repression as an important co-factor for N-Myc oncogenesis, and provide further evidence for the potential application of BET bromodomain inhibitors in the therapy of N-Myc-induced neuroblastoma.]]> Wed 11 Apr 2018 13:01:58 AEST ]]> Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20754 Sat 24 Mar 2018 08:00:25 AEDT ]]>